At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 402 enrolled
Drug / intervention
Insulin Lispro Premix +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of Premixed and Basal-Bolus Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Twice-daily Premixed Insulin
In Brief
A Phase 4 clinical trial evaluating Insulin Lispro Premix, Insulin Glargine, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 402 participants across 14 sites in 3 countries.
Detailed Summary
The purpose of the study is to compare the effects on overall glycaemic control of two insulin intensification therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesChina, South Korea, Taiwan
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartFeb 2011
Primary CompletionNov 2012
TodayJul 2026
First PostedAug 5, 2010
Enrollment StartFeb 1, 2011
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.9 years ago
Interventions
Insulin Lispro Premixdrug
Participant dependent dose, administered subcutaneously for 24 weeks
Insulin Glarginedrug
Participant dependent dose, administered subcutaneously for 24 weeks
Insulin Lisprodrug
Participant dependent dose, administered subcutaneously for 24 weeks